David Wilkinson

Title: David Wilkinson: Innovator in Receptor-Type Tyrosine Kinase Research

Introduction

David Wilkinson is a notable inventor based in West Brunswick, Australia. He has made significant contributions to the field of medical research, particularly in the area of receptor-type tyrosine kinases. With a total of three patents to his name, Wilkinson's work has the potential to impact various therapeutic applications.

Latest Patents

Wilkinson's latest patents include a method for screening for soluble ligands to a receptor-type tyrosine kinase. This invention relates to a method of identifying ligands that interact with receptor-type tyrosine kinases, which are crucial for various cellular processes. The receptor-type tyrosine kinase, in its naturally occurring form, is characterized by its reactivity to monoclonal antibody III.A4, an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and the N-terminal amino acid sequence E L I P Q P. Another significant patent is for an isolated receptor-type tyrosine kinase, which shares similar characteristics and potential applications in medical research.

Career Highlights

Throughout his career, David Wilkinson has worked with prominent organizations such as Amrad Corporation Limited and the Walter and Eliza Hall Institute of Medical Research. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Andrew W Boyd and Richard John Simpson. Their collaborative efforts have further advanced the understanding of receptor-type tyrosine kinases and their implications in medical science.

Conclusion

David Wilkinson's innovative work in receptor-type tyrosine kinase research exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to pave the way for future advancements in therapeutic applications.